Is Extrapolation of the Safety and Efficacy Data in One Indication to Another Appropriate for Biosimilars?

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Stephen B. Hanauer, Brian G. Feagan, Gary R. Lichtenstein et al. · The Lancet · 2002 · 4.2K citations

Veterinary Medicine, Immunology, Pharmacotherapy +12

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

Paul Rutgeerts, William J. Sandborn, Brian G. Feagan et al. · New England Journal of Medicine · 2005 · 3.9K citations · Full text

Pharmacy, Immunology, Pharmacotherapy +14

A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

Stephan R. Targan, Stephen B. Hanauer, Sander J. H. van Deventer et al. · New England Journal of Medicine · 1997 · 3.2K citations · Full text

Pharmacy, Immunology, Inflammation +12

Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis

Peter E. Lipsky, Désirée van der Heijde, E. William St. Clair et al. · New England Journal of Medicine · 2000 · 3K citations · Full text

Medicine, Immunology, Pharmacotherapy +14

Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease

Daniel H. Present, Paul Rutgeerts, Stephan Targan et al. · New England Journal of Medicine · 1999 · 2.7K citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +14